Cabozantinib

Phase 2Active

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Osteosarcoma

Conditions

Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults

Trial Timeline

Nov 22, 2024 → Jun 15, 2028

NCT ID

NCT06341712

About Cabozantinib

Cabozantinib is a phase 2 stage product being developed by Ipsen for Osteosarcoma. The current trial status is active. This product is registered under clinical trial identifier NCT06341712. Target conditions include Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06341712	Phase 2	Active	Nov 22, 2024	Jun 15, 2028	Osteosarcoma
NCT06548867	Pre-clinical	Recruiting	May 28, 2024	Jun 30, 2025	Metastatic Renal Cell Carcinoma
NCT05660954	Phase 2	Active	May 25, 2023	Jun 1, 2026	Differentiated Thyroid Cancer
NCT04511455	Phase 2	Completed	Dec 8, 2020	Dec 31, 2024	Hepatocellular Carcinoma Non-resectable
NCT04204850	Phase 2	Recruiting	Aug 7, 2020	Jun 30, 2026	Hepatocellular Carcinoma
NCT03945773	Phase 2	Completed	Jan 8, 2020	Feb 12, 2026	Locally Advanced or Metastatic Renal Cell Carcinoma
NCT04510688	Pre-clinical	Completed	Oct 23, 2019	Jun 30, 2022	Renal Cell Carcinoma
NCT03729297	Phase 2	Terminated	Sep 5, 2018	Nov 6, 2019	Salivary Gland Cancer

Competing Products

18 competing products in Osteosarcoma

See all competitors

Product	Company	Stage	Hype Score
Azenosertib + Gemcitabine	Zentalis Pharmaceuticals	Phase 1/2	33
Lenvatinib + Ifosfamide + Etoposide + Lenvatinib	Eisai	Phase 2	52
Pemetrexed	Eli Lilly	Phase 2	52
pemetrexed	Eli Lilly	Phase 2	52
Camrelizumab in Combination With Neoadjuvant Chemotherapy	Jiangsu Hengrui Medicine	Phase 2	52
Apatinib	Jiangsu Hengrui Medicine	Phase 2	52
Olaparib + Ceralasertib	AstraZeneca	Phase 2	52
Saracatinib + Placebo	AstraZeneca	Phase 2	52
robatumumab	Merck	Phase 2	52
Pembrolizumab	Merck	Phase 2	52
pazopanib	Novartis	Phase 2	52
Avelumab	Pfizer	Phase 2	51
Nivolumab + Azacitidine	Bristol Myers Squibb	Phase 1	32
Nivolumab + Ipilimumab	Bristol Myers Squibb	Phase 2	51
Cisplatin liposomal	Insmed	Phase 1/2	38
Sm-EDTMP	Jazz Pharmaceuticals	Phase 2	49
LNTH2403 Phase 1 dose + Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).	Lantheus Holdings	Phase 1/2	38
REOLYSIN®	Oncolytics Biotech	Phase 2	44

Other Products from Ipsen

AbobotulinumtoxinA + PlaceboApproved

lanreotide acetateApproved

Tigan® + PlaceboApproved

Diosmectite (Smecta®)Approved

lanreotide (Autogel formulation)Approved